Dimensional Fund Advisors Ltd. : Form 8.3 - Sibanye Gold

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
15
Dimensional Fund Advisors Ltd. : Form 8.3 - Sibanye Gold Limited (trading as Sibanye-Stillwater) - Ordinary shares

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”)

1.         KEY INFORMATION

(a) Full name of discloser:   Dimensional Fund Advisors Ltd. (“Dimensional”), in its capacity as investment manager and on behalf its affiliates who are also investment managers. Dimensional and its affiliates expressly disclaim beneficial ownership of the shares described in this form 8.3
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):   The naming of nominee or vehicle companies is insufficient.  For a trust, the trustee(s), settlor and beneficiaries must be named.    
(c) Name of offeror/offeree in relation to whose relevant securities this form relates:   Use a separate form for each offeror/offeree   Sibanye Gold Limited (ZAE000173951)
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:    
(e) Date position held/dealing undertaken:   For an opening position disclosure, state the latest practicable date prior to the disclosure   7 February 2019
(f)  In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?   If it is a cash offer or possible cash offer, state “N/A”   YES If YES, specify which:   Lonmin plc (GB00BYSRJ698)

2.         POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a)        Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:     NPV Ordinary Shares
      Interests   Short positions
  Number   %   Number   %
(1) Relevant securities owned and/or controlled:   72,944,107*   3.22 %        
(2) Cash-settled derivatives:                  
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:                
    TOTAL:   72,944,107   3.22 %        

*Dimensional Fund Advisors Ltd. and / or its affiliates do not control voting discretion for 7,252,317 shares.

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)        Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:    
Details, including nature of the rights concerned and relevant percentages:    

3.         DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security   Purchase/sale     Number of securities   Price per unit
Ordinary shares   Purchase   164,369   ZAR 13.0039

(b)        Cash-settled derivative transactions

Class of relevant security   Product description e.g. CFD   Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position   Number of reference securities   Price per unit
                 

(c)        Stock-settled derivative transactions (including options)

(i)         Writing, selling, purchasing or varying

Class of relevant security   Product description e.g. call option   Writing, purchasing, selling, varying etc.   Number of securities to which option relates   Exercise price per unit   Type e.g. American, European etc.   Expiry date   Option money paid/ received per unit
                             

(ii)        Exercise

Class of relevant security   Product description e.g. call option   Exercising/ exercised against   Number of securities   Exercise price per unit
                 

(d)        Other dealings (including subscribing for new securities)

Class of relevant security   Nature of dealing e.g. subscription, conversion   Details   Price per unit (if applicable)
             

4.         OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.  If there are no such agreements, arrangements or understandings, state “none”
     

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i)  the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”
     

(c)        Attachments

Is a Supplemental Form 8 (Open Positions) attached?   NO
    8 February 2019
    Thomas Hone
    020 3033 3419

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .  The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk .

 

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Understanding Rollins' Current Market Position and Outlook

Updated Category News Views 226

Analyzing Rollins Inc.'s Stock Performance As we look at the current performance of Rollins Inc. (NYSE: ROL), the shares are trading around $55.73, reflecting a decrease of 1.24% in the recent session. While the stock has dipped by 3.81% over the past month, it has impressively increased by 10.91% year-over-year. This presents a curious juxtaposition of short-term...

Continue Reading
Silver One Reports Major Mineral Resource Estimate for Candelaria

Updated Category News Views 199

Candelaria Project Mineral Resource Estimate Silver One Resources Inc. (OTCQX: SLVRF) has made a significant announcement regarding the completion of a mineral resource estimate for the Candelaria Project. This estimate is prepared in accordance with the National Instrument 43-101, ensuring that the resources are assessed with high standards of transparency and accuracy....

Continue Reading
Investors Alert: Zynex (ZYXI) Faces Serious Legal Scrutiny

Updated Category News Views 197

Legal Investigation into Zynex, Inc. The Law Offices of Frank R. Cruz have announced a crucial investigation regarding Zynex, Inc. (ZYXI) focused on potential violations of federal securities laws. This investigation comes as a response to significant concerns raised about the company's recent financial disclosures and their implications for investors. Understanding the...

Continue Reading
Understanding Rentokil Initial's Stock Valuation Insights

Updated Category News Views 100

Assessing Rentokil Initial's Stock Performance In the current trading session, Rentokil Initial Inc. (NYSE: RTO) shares are priced at $26.42, witnessing a notable increase of 1.46%. Over the past month, the stock has gained 1.40%, though it has faced a decline of 7.78% in the last year. This fluctuation raises questions among shareholders regarding its valuation, despite...

Continue Reading
Innovative Insights on Efzofitimod from aTyr Pharma's Recent Conference

Updated Category News Views 177

aTyr Pharma Highlights Efzofitimod at Key Conference At a significant scientific gathering, aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology firm known for its innovative therapeutic approaches, shared compelling data concerning efzofitimod. This presentation underlined important insights about the treatment of pulmonary sarcoidosis. The conference, which...

Continue Reading